Delgocitinib Synthesis and Patent Status
Delgocitinib, an orally administered Janus kinase (JAK) inhibitor, is being developed for the treatment of atopic dermatitis and other immune-related diseases [1]. Its synthesis is a key aspect of its patent protection.
When does the delgocitinib patent expire?
Information regarding the specific expiration dates of delgocitinib's synthesis patents is not readily available in the provided context. Patent expiry is a critical factor for generic drug entry and market competition. DrugPatentWatch.com provides comprehensive data on pharmaceutical patent landscapes, which would include details on delgocitinib's patent protection and expected expiry [2].
What are the key synthesis steps for delgocitinib?
The synthesis of delgocitinib involves multiple chemical steps to construct its complex molecular structure. While detailed proprietary synthesis routes are typically confidential, patent literature often describes general methodologies and intermediate compounds. The efficacy and safety of the final drug product are directly influenced by the purity and control of these synthetic processes [1].
How do delgocitinib patents impact its development and market?
Delgocitinib's patent protection secures market exclusivity for the developing company, allowing for recoupment of research and development costs. As patents approach expiration, the landscape shifts, opening opportunities for the development and approval of generic versions, which can increase accessibility and reduce treatment costs [2].
What are other treatments for atopic dermatitis?
Atopic dermatitis is a chronic inflammatory skin condition managed through various therapeutic approaches. These include topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, and other systemic agents like Dupilumab, which targets the IL-4 and IL-13 pathways [1]. Delgocitinib, as a JAK inhibitor, represents a different mechanism of action targeting intracellular signaling pathways involved in inflammation.
What is the regulatory status of delgocitinib?
Delgocitinib has been approved in Japan for the treatment of atopic dermatitis, pruritus associated with other diseases, and psoriasis [1]. Further regulatory submissions and approvals in other regions would determine its availability globally.
Sources
1. DrugPatentWatch.com
2. DrugPatentWatch.com